"I feel a great sense of meaning from my work and am privileged to be working for Genentech as a clinical pharmacologist lead on many transformative programs."
Prior to joining Genentech, I worked at Novartis and Ionis Pharmaceuticals supporting the development of several large and complex molecules. At Genentech I have been supporting the Oncology Clinical Pharmacology strategy for several combination cancer immunotherapy programs. Some of the clinical development areas I have worked on include Phase 1-3 studies, special population assessments, organ impairment, material bridging, pediatric studies, ethnic sensitivity, and drug-drug interaction liabilities.
The work environment and culture of Genentech have been a place of constant stimulation, positive energy, and passion for me. Developing transformative medicines and offering new hopes for patients are Genentech’s top priorities and commitments. In this short time, I have already had the privilege to sense the impact of my work and am continuously being challenged with excellent opportunities to learn and grow, and have established a strong connection and sense of pride to be a member of Genentech family.
Nucleic Acid Therapeutics 26:223-35.
Shemesh CS, Yu R, Gaus H, Seth P, Bennett F, Geary R, Henry S, and Wang Y. (2016).
My job focuses on the clinical pharmacology aspects of several cancer immunotherapy and personalized cancer therapy development programs. Understanding of disposition characteristics and exposure-response of several novel agents across longitudinal trial data is a key focus along with evaluation of dosing schedules and relationships to outcomes.
Transformation of knowledge and health authority interactions are one of the remarkable features of the job which I admire. Genentech has been a place for me to expand my scientific knowledge and skill-sets while working on several submissions in support of novel oncology therapeutics.